Results 141 to 150 of about 48,956 (312)
Headache: The Journal of Head and Face Pain, EarlyView.Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza +27 more
wiley +1 more source
The Journal of Headache and PainBackground Calcitonin Gene-Related Peptide (CGRP) is involved in migraine pain signaling, and blockage hereof is effective in migraine treatment. Headache in idiopathic intracranial hypertension (IIH) is often migraine-like but the underlying mechanisms ...
Nadja Skadkær Hansen +5 more
doaj +1 more source
Rapid nitric oxide‐ and prostaglandin‐dependent release of calcitonin gene‐related peptide (CGRP) triggered by endotoxin in rat mesenteric arterial bed [PDF]
, 1996 Xian Wang +4 more
openalex +1 more source
Can atogepant be a preventive treatment for cluster headache?—Insights from a case series
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão +3 more
wiley +1 more source
CGRP Antibodies as Prophylaxis in Migraine
Cell, 2018 Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018.
openaire +3 more sources
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima +11 more
wiley +1 more source
The effect of calcitonin gene-related peptide (CGRP) on cerebrovascular system in dogs
, 1987 Ichiro Ikegaki +4 more
openalex +1 more source
Acute Ischemic Chest Pain is not Associated with Increased Calcitonin Gene-Related Peptide (CGRP) Levels in Peripheral Plasma nor in the Coronary Circulation [PDF]
, 1999 Tore Eliasson Peter Währborg
openalex +1 more source